JP2020536972A5 - - Google Patents

Info

Publication number

JP2020536972A5

JP2020536972A5 JP2020542191A JP2020542191A JP2020536972A5 JP 2020536972 A5 JP2020536972 A5 JP 2020536972A5 JP 2020542191 A JP2020542191 A JP 2020542191A JP 2020542191 A JP2020542191 A JP 2020542191A JP 2020536972 A5 JP2020536972 A5 JP 2020536972A5

Authority

JP

Japan

Prior art keywords

pharmaceutical composition

aqueous pharmaceutical

aqueous

composition according

cyclodextrin

Prior art date

2018-10-15

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Pending

Links

• Espacenet
• Global Dossier
• Discuss

• 239000008194 pharmaceutical composition Substances 0.000 claims 16
• ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 claims 8
• 239000007864 aqueous solution Substances 0.000 claims 7
• ACCMWZWAEFYUGZ-UHFFFAOYSA-N bilastine Chemical compound N=1C2=CC=CC=C2N(CCOCC)C=1C(CC1)CCN1CCC1=CC=C(C(C)(C)C(O)=O)C=C1 ACCMWZWAEFYUGZ-UHFFFAOYSA-N 0.000 claims 4
• 229960004314 bilastine Drugs 0.000 claims 4
• 238000000034 method Methods 0.000 claims 4
• 229920002678 cellulose Polymers 0.000 claims 3
• 239000001913 cellulose Substances 0.000 claims 3
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
• 150000002170 ethers Chemical class 0.000 claims 3
• QLIIKPVHVRXHRI-CXSFZGCWSA-N mometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CCl)(O)[C@@]1(C)C[C@@H]2O QLIIKPVHVRXHRI-CXSFZGCWSA-N 0.000 claims 3
• 150000003839 salts Chemical class 0.000 claims 3
• 239000012453 solvate Substances 0.000 claims 3
• 239000000375 suspending agent Substances 0.000 claims 3
• 206010010741 Conjunctivitis Diseases 0.000 claims 2
• 239000007900 aqueous suspension Substances 0.000 claims 2
• 229920003086 cellulose ether Polymers 0.000 claims 2
• 201000010099 disease Diseases 0.000 claims 2
• 239000006185 dispersion Substances 0.000 claims 2
• 150000002148 esters Chemical class 0.000 claims 2
• 229960001664 mometasone Drugs 0.000 claims 2
• 238000011321 prophylaxis Methods 0.000 claims 2
• 238000011282 treatment Methods 0.000 claims 2
• 206010039085 Rhinitis allergic Diseases 0.000 claims 1
• 230000000172 allergic effect Effects 0.000 claims 1
• 201000010105 allergic rhinitis Diseases 0.000 claims 1
• 208000006673 asthma Diseases 0.000 claims 1
• 208000010668 atopic eczema Diseases 0.000 claims 1
• 239000003795 chemical substances by application Substances 0.000 claims 1
• 208000035475 disorder Diseases 0.000 claims 1
• 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
• 208000027866 inflammatory disease Diseases 0.000 claims 1
• 230000003211 malignant effect Effects 0.000 claims 1
• 239000000203 mixture Substances 0.000 claims 1
• 229960002744 mometasone furoate Drugs 0.000 claims 1
• WOFMFGQZHJDGCX-ZULDAHANSA-N mometasone furoate Chemical compound O([C@]1([C@@]2(C)C[C@H](O)[C@]3(Cl)[C@@]4(C)C=CC(=O)C=C4CC[C@H]3[C@@H]2C[C@H]1C)C(=O)CCl)C(=O)C1=CC=CO1 WOFMFGQZHJDGCX-ZULDAHANSA-N 0.000 claims 1
• 239000006199 nebulizer Substances 0.000 claims 1
• 208000037916 non-allergic rhinitis Diseases 0.000 claims 1
• 230000002062 proliferating effect Effects 0.000 claims 1
• 206010039083 rhinitis Diseases 0.000 claims 1
• 238000003756 stirring Methods 0.000 claims 1
• 239000004094 surface-active agent Substances 0.000 claims 1